Intercept Pharmaceuticals Announces Positive Phase II Results For INT-747 As A Treatment For Primary Biliary Cirrhosis
Links shared publicly online about this topic.
- 1,644total visits
Intercept Pharmaceuticals Announces Positive Phase II Results For INT-747 As A Treatment For Primary Biliary Cirrhosis
View full resource at medicalnewstoday.com
Tags: Liver Condition, Cirrhosis, Pharma, Clinical Trial
Most Recently Shared on October 28, 2009 at 12:22 pm By:
Intercept Pharmaceuticals Announces Positive Phase II Results For INT-747 As A Treatment For Primary Biliary Ci.. http://bit.ly/R4ctg
Phase 2 Study of Obeticholic Acid (INT-747) for Primary Biliary Cirrhosis - MPR
empr.com — “Intercept Pharmaceuticals announced positive results from its Phase 2 study of obeticholic acid (OCA or INT-747) as monotherapy for the treatment of primary biliary cirrhosis (PBC).” View full resource at empr.com
Most Recently Shared on April 1, 2011 at 4:09 pm By:
MPR News: Phase 2 Study of Obeticholic Acid (INT-747) for Primary Biliary Cirrhosis: Intercept Pharmaceuticals a... http://bit.ly/gvjDyJ
Intercept Pharmaceuticals Presents Positive Phase II Results From Study Of INT-747 Therapy In Primary Biliary Cirrhosis At EASL
medicalnewstoday.com — “Intercept Pharmaceuticals, Inc., announced the presentation of the results from its recently completed Phase II clinical trial of INT-747 (obeticholic acid) in patients with primary biliary cirrho” View full resource at medicalnewstoday.com
Most Recently Shared on April 14, 2010 at 6:08 pm By:
MNT Pharma News Health News and Pharma
Intercept Pharmaceuticals Presents Positive Phase II Results From Study Of INT-747 Therapy In Primary Biliary Cirrhosi... http://mnt.to/3BcF
Advertisement
